PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

This trial tests a combination of two drugs — PBF-1129 (a new oral pill) and nivolumab (an immunotherapy) — for patients with advanced non-small cell lung cancer (NSCLC) that has come back or spread after prior treatment. **You may be eligible if...** - You are 18 or older with advanced or metastatic NSCLC that cannot be cured - You have already received standard chemotherapy and immunotherapy (including a PD-1/PD-L1 drug) - You are in generally good physical condition (able to carry out daily activities) - Your liver, kidneys, and blood counts are within acceptable ranges - You are able to swallow pills **You may NOT be eligible if...** - You have an active autoimmune disease requiring treatment - You have untreated or worsening brain metastases - You have had severe side effects (grade 3 or higher) from prior immunotherapy - You are pregnant or breastfeeding - You have HIV, active hepatitis B or C, or liver cirrhosis Talk to your doctor to see if this trial is right for you.